Really getting sick of the back and forth with SYNTA. I just joined ultimatestockalerts (google em) a month ago and have already locked in close to 20% gains with their calls.
Wow, what a truly absurd post. DNDN and SNTA are nothing alike. Provenge is a very labor intensive treatment with high upfront costs and suited to a single cancer. Ganetespib is has a relatively low side-effect profile which makes it amenable to many combination therapies, and it has indications of being broad anti-cancer agent. The Hsp90i conjugates are quite intriguing. Unfortunately, SNTA management has been horrid. The conjugates have little value until they make into trials, and management has not yet provided any timetable for that.
Gutterman- no one knows what the results will be on the trials. Phase 3 successes are typically rare. This one has been de-risked, but even if you don't believe that, how is peppering the site with your personal opinions a good use of your time or those who read this blog? Say your peace, and then move on. By all means, add to the blog when there is objective information or a opinion based upon facts, but why spend your time beating this stock up? If you are bearish, sell it short!
As best as I understand it,when shorts cover,the stock price moves up.
Shorts start to cover when the trend changes.
I believe that the shorting institutions are moving to stocks that are over valued.
IMO,not only are they covering but establishing long positions at low prices on SNTA.
SNTA is undervalued based on prospects.
With adequate money through the end of 2015,that gives a year to announce many positive items before cash is an issue.
gutterman...are you short on SNTA or just looking for attention?
What did I miss?The low was $2.62.
Let's continue this conversation at the end of 2014 or Q4 E/R
Premium Research for SNTA
Zacks Rank [?] Rank Change Trend Buy 2
Zacks Industry Rank 55 / 265 (Top 21%)
Sentiment: Strong Buy
gutterman.....thanks for the advice and warning.
I was very confused about my investment and you have clarified this for me.
You should be commended for taking time out of your busy schedule to help the clueless.
I will be buying more..............IMO this week may be slightly down but the trend is up
DNDN was a one pony show. So is SNTA.
By Peg Brickley And Jeffrey Ng
Dendreon Corporation filed for Chapter 11 bankruptcy protection Monday after coming to terms with senior lenders on a restructuring that could mean a reorganization or a sale of its cancer drug operation.
In a news release, the Seattle company said the bankruptcy filing will allow continued delivery of its Provenge prostate cancer treatment. In a filing with the U.S. Bankruptcy Court in Wilmington, Del., Dendreon general counsel Robert Crotty said the company raised money based on expectations the drug would bring in billions in revenue, but found the drug was slower to catch on than expected.
Holders of 84% of a $620 million issue of convertible senior notes have signed a restructuring support agreement that calls for their debt to be converted to equity in a reorganized company. The support agreement is the result of talks with, among others, Deerfield Management Company, L.P., the largest holder of the debt issue, court papers say.
While it pursues a Chapter 11 turnaround, Dendreon will launch a court-supervised sale process, looking for a buyer that will continue producing the drug. Potential bidders will have to provide value of at least $275 million, Dendreon said. Companies in bankruptcy often file with a reorganization strategy in mind, but test the market by putting their assets up for auction. Court papers say efforts to sell Dendreon privately near the end of 2013 produced no bidders.
Dendreon filed for protection with $100 million in cash or cash equivalents, and won't need bankruptcy financing, according to the release.
As of the period ending Sept. 30, 2014, Dendreon had $340 million in assets and $660.7 million in liabilities on a book value basis. When hopes for Provenge were running high, Dendreon had 1,500 employees. Cost-containment efforts have reduced the workforce to 698 people, court papers say.
When Provenge won approval from the Food and Drug Administration in 2010, it was touted as ushering in a new era of treatments to marshal the immune system against cancer. But it never really gained traction in the market.
Its $93,000 price for a treatment that improved median survival by just over four months was one reason. Management missteps in understanding the market, including the fact that doctors had to pay for the complex treatment up front amid initial uncertainty over insurance reimbursement was another.
Then came competition. Johnson & Johnson's Zytiga was approved for advanced prostate cancer in 2011 followed by Xtandi from Medivation Inc. of San Francisco and Astellas Pharma Inc. of Japan.
Both were pills that were easy to prescribe, required no upfront investment for doctors and were backed by clinical trial data doctors were more comfortable with. In the face of these rivals, Provenge's market share was under 5%, according to one recent analyst report.
Ron Winslow contributed to this article.
Thanks! I'll let my niece, who had cancer as a smaill child and just graduated from college, know that the chemo was a waste of time. You are really a piece of human excrement.
Sentiment: Strong Buy
So i am off a little. Was not on DNDN and SNTA is so like it. I have 20 more years to wait around if i do not get cancer and die 1st. There will never be a cure for cancer. Only snake oil that delays a slow painful death. Anyone in an advanced stage will die so these studies are useless. SNTA by way of DNDN by 2017.
Sentiment: Strong Sell
Synta Pharmaceuticals Corp. reported that the Company has been invited by the U.S. Food and Drug Administration to participate in a meeting of the Oncologic Drugs Advisory Committee's Pediatric Subcommittee on December 11.
According to a media release, the purpose of the meeting is to inform the FDA as to whether there is sufficient interest in the pediatric investigator community to warrant the FDA issuing a Pediatric Written Request to Synta. If the FDA issues a Pediatric Written Request and Synta fulfills its requirements, an additional six months of exclusivity will be granted to ganetespib. At the meeting, the subcommittee will review the SARC 023 study, investigating ganetespib in patients with malignant peripheral nerve sheath tumors and other sarcomas. Ganetespib is a next-generation inhibitor of the chaperone protein Hsp90, which is critical for the activation and stability of numerous proteins that control malignant tumor growth. Ganetespib has been studied in over 1,200 adult patients to date.
SARC 023, sponsored by the Sarcoma Alliance for Research through Collaboration, is an open label Phase 1/2 trial of ganetespib in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma, including MPNST. The Principal and Co-Principal Investigators are AeRang Kim, MD, PhD, of the Children's National Medical Center and Brigitte Widemann, MD, Section Head, National Cancer Institute Pediatric Oncology Branch. The Pediatric Subcommittee of ODAC will review the design of SARC 023, as well as pre-clinical data demonstrating the scientific rationale for studying this combination in a clinical trial.
"Outcomes for unresectable, recurrent, or metastatic MPNST are very poor, underscoring an urgent need for new therapeutic options," said Dr. Vojo Vukovic, Chief Medical Officer, Synta. "Drugs that target Hsp90 and mTOR have shown synergistic activity in MPNST animal models. If the combination proves safe and effective in patients, it may provide an important new therapeutic strategy for this disease. We look forward to discussing the current clinical experience with ganetespib as well as the ongoing SARC 023 study with the FDA and Pediatric Subcommittee
The Wall Street analysts recommendations and price targets barely carry any weight anymore. I have owned several Bios with broad buy recommendations that hardly move at all...when they say their buying; they are selling ..and vice versa.
i agree , my buy in was 3.30 im out if it hits 4.30 , will keep a little for long term...
what kind of a bogus price target is that. these guys keep losing credibility when they put out these insane price targets.